Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Joint Statement By The Royal Pharmaceutical Society Of Great Britain And The College Of Pharmacy Practice
- Forest Laboratories, Inc. And Gedeon Richter Announce Positive Results From A Phase IIb Study Of Cariprazine For The Treatment Of Schizophrenia
- RSNA: Appendicitis? There's an App for That
- Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia (AML)
- Crucell Announces Positive Results Of Phase II Rabies Monoclonal Antibody Combination Clinical Study In Philippines
- Zetiq Reports Success In Clinical Trial Aimed For Early Identification Of Cervical Cancer
- Jazz Pharmaceuticals Submits New Drug Application For JZP-6 (sodium Oxybate) For The Treatment Of Fibromyalgia
- FDA Warns of Fatal Overdose Risk with Propoxyphene
- Forest Laboratories Presents Analysis Of Two Positive Pivotal Phase III Studies Of Ceftaroline For The Treatment Of Community-Acquired Pneumonia (CAP)
- NuPathe Reports Positive Phase III Results For Zelrix, A Novel Transdermal Patch For Acute Migraine
Quantum Immunologics, A Major Mentor Capital Investee, Starts FDA-Authorized Breast Cancer Trials
Posted by: admin in Pharmacy Drugs on August 21st, 2009
Mentor Capital, Inc. (Pink Sheets:MNTR) announces that Quantum Immunologics, Inc. (QI) has met a significant milestone marking the beginning of its FDA-authorized breast cancer trial, the completion of the first clinical treatment injection.
Mentor Capital, Inc. is the largest single shareholder in QI and looks to provide equity funding throughout the trials, assist QI in funding future strategic stock or cash acquisitions, and to stand by as a preferred funding source for QI during later stage or additional trials. Calculated at the current QI private placement price, Mentor Capital holds approximately $3.74 in QI stock per Mentor share, and QI represents the majority of Mentor Capital’s portfolio assets.
Quantum Immunologics is based in Tampa, Florida and focuses on cancer immunotherapies. This research and development company is currently sponsoring and conducting an FDA-authorized Phase I/II clinical trial testing the safety and efficacy of its immunotherapy on twenty-seven Stage IV breast cancer patients who have failed conventional therapy. The first patient in the breast cancer trial has begun to receive QI’s dendritic cell therapy. According to Mr. Chuck Broes, CEO of QI, “This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome.”
Chet Billingsley, CEO of Mentor Capital, adds, “The successful initiation of concurrent Phase I/II trials represents an important step in the value equation for QI. Comparing the cost to acquire 20% of other dendritic immunotherapy companies, like Dendreon (DNDN), with Mentor Capital, which holds 20% of QI, will reveal attractive buying opportunities for biotechnology investors, now that QI is at the clinical stage.”
QI’s clinical trial is designed around the use of QI’s proprietary dendritic cell therapy, which employs oncofetal antigen (OFA) to recruit the patient’s own immune system to target and attack the cancer cells with the intent to improve patient survivability and quality of life. Each patient will receive three monthly injections of the patient’s own dendritic cells that have been sensitized to OFA. It is anticipated that once the sensitized cells are injected back into the patient, the patient’s T-cells will locate the OFA found on the patient’s cancer cells, thereby generating an immune response with the goal of killing the cancer cells and preventing further spread of the disease.
Further information on Quantum Immunologics, including a summarizing video of the QI breast cancer treatment methodology that is now in FDA trials, may be found at their company web site: http://www.QuantumImmunologics.com. Comprehensive information on Mentor Capital, including capital structure detail, can be found at: http://www.MentorCapital.com. Level II quotes, news, financial information and trading charts may be referenced at http://www.PinkSheets.comunder the trading symbol MNTR.
Source
Quantum Immunologics
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.